Plaque Psoriasis

Results of several clinical trials demonstrated the superior efficacy of risankizumab compared with apremilast or placebo.

Benjamin Lockshin, MD, explains the current landscape of oral medications for plaque psoriasis, emerging developments in treatment, and the importance of shared decision-making.

The approval for the IL-17A and IL-17F inhibitor is supported by data showing about 80% of patients achieved nearly clear skin within 4 doses.

This new post-hoc analysis of ruxolitinib cream for those with eczema indicates that continued treatment past 8 weeks may lead to further benefit for those with the skin disease.

Lauren Miller, MPAS, PA-C; and Jayme Heim, MSN, FNP-BC, share approaches to implementing the newly approved TYK2 inhibitor, deucravacitinib, into the treatment algorithm of plaque psoriasis.

Jayme Heim, MSN, FNP-BC, compares the efficacy, safety and dosing of 2 oral therapies, apremilast and deucravacitinib, for the treatment of plaque psoriasis.

The new data on this drug’s effects on maintenance of clinical response indicates the strength of the treatment for individuals with the immune-mediated skin disease.

This new data on the negative impacts of skin disease on individuals in 27 countries in Europe demonstrates the lasting impacts of stigmatization.

This new data from 27 European countries resulted in several notable findings with regard to the journey of patients with skin disease in various healthcare environments.

Experts in dermatology review the efficacy and safety of deucravacitinib in the treatment of plaque psoriasis, a recently approved oral TYK2 inhibitor.

Jayme Heim, MSN, FNP-BC; and Lauren Miller, MPAS, PA-C, share thoughts on the use of oral systemic and biologic treatments in plaque psoriasis, commenting on the need for personalized care for patients.

This announcement by Arcutis broadens the psoriasis drug’s indication and was done to help simplify management of the skin condition for younger patients as well.

An expert nurse practitioner comments on recent advances in the treatment of plaque psoriasis, as well as the continuous need for more treatment options.

Lauren Miller, MPAS, PA-C; and Jayme Heim, MSN, FNP-BC, discuss the role of advanced practice providers (APPs) within dermatology, highlighting the medical, surgical, and cosmetic categories in the space.

This new data should be taken into account before biologics prescriptions are made for patients with conditions such as psoriasis.

A study from UCSD highlights how advances in imaging modalities and utilization could aid in the early detection of psoriatic arthritis.

This new qualitative data may be helpful both for patient-centric decision-making for clinicians as well as endpoints in future research on prurigo nodularis.

A study of more than 500 patients with severe psoriasis provides further insight into the association between severe psoriasis and cardiovascular disease risk, demonstrating coronary microvascular dysfunction was present in 30% of this cohort.

The company shared anticipation that their BLA decision for bimekizumab to treat adults with plaque psoriasis will not come before the end of this month.

In this interview segment, Jayme Heim, MRS, explored promising treatments on the horizon, hidradenitis suppurativa, and future research on teledermatology and artificial intelligence.

This interview with Jayme Heim featured a discussion about some of the latest treatment-related news for atopic dermatitis and psoriasis.

The use of this scoring system twice-per-week may help patients to better manage their mild-to-moderate atopic dermatitis.

This new research demonstrated that when TNF-inhibition is effective, a shift to brodalumab treatment may be useful in suppression of psoriasis and improvement of patients’ quality of life.

Ashfaq Marghoob, MD, discusses his recent workshop presentation on dermoscopies for skin cancer.

The multi-center study led to several important findings, one of which being that history of biologic-use could be a factor of importance in secukinumab retention prediction.